Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Wednesday, May 2, 2018

Customized Brain Cells for Stroke Patients Using Pluripotent Stem Cells

Going for a moon shot rather than tackling the solvable problems in stroke or the 5 causes of the neuronal cascade of death
This crapola is why stroke survivors need to be in charge. Damn we need stroke leadership and we need it NOW.
http://stroke.ahajournals.org/content/49/5/1091.long
Zaal Kokaia, Irene L. Llorente, S. Thomas Carmichael
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Regenerative medicine in stroke involves therapies that induce tissue repair and recovery. This is a distinct approach from reducing stroke damage: restoring blood flow, reducing cell death, or limiting secondary progression of injury. These 3 areas have a very concise or limited focus: restoring blood flow involves lysing or removing clots. Reducing cell death means neuroprotection. Limiting secondary damage involves modulating process of inflammation or delayed apoptosis. In contrast, tissue regeneration after stroke relates to many potential therapeutic targets, such as enhancing angiogenesis, neurogenesis, or gliogenesis; promoting axonal sprouting; stabilizing injured synaptic connections; or modulating excitatory/inhibitory balance in brain circuits. Single molecular targets may promote 1 specific tissue repair process, but clinical success is likely to occur if many of these reparative events are stimulated by 1 therapeutic treatment. This concept has informed the stem cell field in stroke. In experiments with transplantation of stem/progenitor cells in stroke, tissue repair can occur through direct formation of or replacement to neurons or glia, production of growth factors and cytokines, and stimulation of the cellular progenitors that lead to angiogenesis, neurogenesis, and gliogenesis.
Tissue repair and recovery after stroke has been shown with the first wave of studies in the field: the application of the easiest to produce stem or progenitor cells, such as adult progenitor cells (mesenchymal stromal cells, multipotent adult progenitor cells, hematopoietic stem/progenitor cells) or very early neural precursor cells that are differentiated from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs). With adult progenitor cells, isolation and expansion of the cells is relatively straightforward and application to stroke has progressed into 2 clinical trial efforts (Athersys, SanBio). The differentiation of ESCs or iPSCs into a very early neural precursor is a default cellular program and can be done with relatively simple methods. As a result, ESC- …
View Full Text

No comments:

Post a Comment